Back HCV Treatment

ICAAC 2014: AbbVie 3D Hepatitis C Regimen Is Well-Tolerated in Phase 3 Trials

AbbVie's 3D hepatitis C regimen containing paritaprevir (ABT-450), ombitasvir, and dasabuvir was generally well-tolerated in the Phase 3 SAPPHIRE trials, according to a pooled analysis presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC. While most patients experienced some adverse events, serious side effects were rare and few people discontinued treatment early for this reason.


Read more: